Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew A Bolinger

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|September 21, 2023
RIPTACs: A groundbreaking approach to drug discoveryZonghui Ma, Andrew A Bolinger, Jia Zhou
Expert Opinion on Drug Discovery|March 10, 2023
Novel approaches to targeted protein degradation technologies in drug discoveryYu Xue, Andrew A Bolinger, Jia Zhou
Current Topics in Medicinal Chemistry|March 6, 2024
Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023Saghir Ali, Andrew A Bolinger, Jia Zhou
Journal of Medicinal Chemistry|August 14, 2023
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)Zonghui Ma, Andrew A Bolinger, Haiying Chen, et al.
Expert Opinion on Therapeutic Patents|September 2, 2024
An updated patent review of BRD4 degradersZonghui Ma, Cun Zhang, Andrew A Bolinger, et al.
Expert Opinion on Therapeutic Targets|January 30, 2023
Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeuticsZonghui Ma, Andrew A Bolinger, Jia Zhou, et al.
Expert Opinion on Drug Discovery|July 30, 2024
Lessons learnt from broad-spectrum coronavirus antiviral drug discoveryAndrew A Bolinger, Jun Li, Xuping Xie, et al.
Advances in Pharmacology (San Diego, Calif.)|November 9, 2024
BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel diseaseZonghui Ma, Andrew A Bolinger, Irina V Pinchuk, et al.
ACS Chemical Neuroscience|September 7, 2023
Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic TargetAndrew A Bolinger, Andrew Frazier, Jun-Ho La, et al.
Drug Discovery Today|April 12, 2026
Artificial intelligence revolutionizing CNS drug discovery and developmentMd E K Talukder, Mohammad R Islam, Saghir Ali, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|September 21, 2023
RIPTACs: A groundbreaking approach to drug discoveryZonghui Ma, Andrew A Bolinger, Jia Zhou
Expert Opinion on Drug Discovery|March 10, 2023
Novel approaches to targeted protein degradation technologies in drug discoveryYu Xue, Andrew A Bolinger, Jia Zhou
Current Topics in Medicinal Chemistry|March 6, 2024
Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023Saghir Ali, Andrew A Bolinger, Jia Zhou
Journal of Medicinal Chemistry|August 14, 2023
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)Zonghui Ma, Andrew A Bolinger, Haiying Chen, et al.
Expert Opinion on Therapeutic Patents|September 2, 2024
An updated patent review of BRD4 degradersZonghui Ma, Cun Zhang, Andrew A Bolinger, et al.
Expert Opinion on Therapeutic Targets|January 30, 2023
Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeuticsZonghui Ma, Andrew A Bolinger, Jia Zhou, et al.
Expert Opinion on Drug Discovery|July 30, 2024
Lessons learnt from broad-spectrum coronavirus antiviral drug discoveryAndrew A Bolinger, Jun Li, Xuping Xie, et al.
Advances in Pharmacology (San Diego, Calif.)|November 9, 2024
BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel diseaseZonghui Ma, Andrew A Bolinger, Irina V Pinchuk, et al.
ACS Chemical Neuroscience|September 7, 2023
Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic TargetAndrew A Bolinger, Andrew Frazier, Jun-Ho La, et al.
Drug Discovery Today|April 12, 2026
Artificial intelligence revolutionizing CNS drug discovery and developmentMd E K Talukder, Mohammad R Islam, Saghir Ali, et al.
Pageof 2